engleski

Glucagon-like peptide-1 receptor agonists decreases albuminuria in overweight patients with type 2 diabetes

The results of our study suggest that therapy with GLP-1 receptor agonists liraglutide and exenatidemay significantly reduce UAE in overweight T2DM. It has been suggested that GLP-1 receptor agonists has a crucial role in protection against increased renal oxidative stress under chronic hyperglycemia via inhibition of NAD(P)H oxidase and PKA activation which resulted in reduced albuminuria and mesangial expansion.

glucagon-like peptide-1; albuminuria; type 2 diabetes

nije evidentirano